Prostate Cancer, Androgen Deprivation Therapy, Obesity, the Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease: A Review
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Prostate cancer is the most frequently diagnosed malignancy among UK men and accounts for 12% of male deaths. Androgen deprivation therapy (ADT) is commonly used as part of the treatment for prostate cancer. It is effective at suppressing prostate-specific antigen, stabilizing disease, alleviating symptoms in advanced disease, and potentially prolonging survival. However ADT, presumably at least in part owing to low testosterone levels is associated with insulin resistance, the development of metabolic syndrome plus increased overall and cardiovascular disease mortality. We have reviewed the relationship between prostate cancer, ADT, metabolic syndrome, type 2 diabetes, and cardiovascular disease. We have not reviewed other potential medical problems such as osteoporosis. We suggest that there should be a baseline assessment of patients' risk for cardiovascular disease before starting ADT. Consideration should be given to starting appropriate therapies including lifestyle advice, antihypertensive and lipid-lowering agents, insulin sensitizer, plus possibly aspirin. Having started ADT, the patients should have a regular (possibly annual) assessment of their cardiovascular risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Brain Insulin Receptor in Control of Body Weight and Reproduction
Brüning, J. C., Gautam, D., Burks, D. J., Gillette, J., Schubert, M., Orban, P. C., Klein, R., Krone, W., Müller-Wieland, D., & Kahn, C. R. (2000) · Science · doi:10.1126/science.289.5487.2122 · Cited by 2,235
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Albuminuria reflects widespread vascular damage: The Steno hypothesis
Deckert, T., Feldt-Rasmussen, B., Borch-Johnsen, K., Jensen, T., & Kofoed-Enevoldsen, A. (1989) · Diabetologia · doi:10.1007/bf00285287 · Cited by 1,400
Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., Salonen, R., & Salonen, J. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1036 · Cited by 920 · cited 2×
“Cross-sectional studies in healthy men have shown an inverse relationship between total testosterone and free testosterone levels with raised insulin resistance and insulin concentrations.(22,23) Low testosterone levels have also been found to be associated with hypertension.”
BackgroundKapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791 · cited 1×
“Two further studies of type 2 diabetic men using oral testosterone showed an improvement in insulin resistance and glycemic control.(34,35) However, Corrales et al(36) reported a neutral effect using intramuscular testosterone and Basu et al(37) did not demonstrate any benefit with testosterone patch therapy in elderl…”
BackgroundMalkin, C. J., Pugh, P. J., Jones, R. D., Kapoor, D., Channer, K. S., & Jones, T. H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031069 · Cited by 731
Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes
Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0804 · Cited by 631 · cited 1×
“It is reported that androgen deficiency in type 2 diabetes is commonly associated with hypogonadotropic hypogonadism.(27) It is suggested that insulin resistance determines a reduction in insulin action in the thalamus leading to hypogonadotropic hypogonadism.”
BackgroundStellato, R. K., Feldman, H. A., Hamdy, O., Horton, E. S., & McKinlay, J. B. (2000) · Diabetes Care · doi:10.2337/diacare.23.4.490 · Cited by 618
Oh, J.-Y., Barrett-Connor, E., Wedick, N. M., & Wingard, D. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.55 · Cited by 594 · cited 1×
“Similarly, longitudinal studies have demonstrated that lower testosterone levels independently predict the development of insulin resistance, metabolic syndrome, and type 2 diabetes.(25,26) The cause of the low testosterone in type 2 diabetes remains obscure.”
BackgroundAndrogen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
Saigal, C. S., Gore, J. L., Krupski, T. L., Hanley, J., Schonlau, M., & Litwin, M. S. (2007) · Cancer · doi:10.1002/cncr.22933 · Cited by 542
D'Amico, A. V., Denham, J. W., Crook, J., Chen, M.-H., Goldhaber, S. Z., Lamb, D. S., Joseph, D., Tai, K.-H., Malone, S., Ludgate, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3369 · Cited by 501
Insulin sensitivity during combined androgen blockade for prostate cancer
Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493
Boyanov, M. A., Boneva, Z., & Christov, V. G. (2003) · The Aging Male · doi:10.1080/tam.6.1.1.7 · Cited by 381
ZUMOFF, B., STRAIN, G. W., MILLER, L. K., ROSNER, W., SENIE, R., SERES, D. S., & ROSENFELD, R. S. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-4-929 · Cited by 349
Androgens, insulin resistance and vascular disease in men
Kapoor, D., Malkin, C. J., Channer, K. S., & Jones, T. H. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02299.x · Cited by 317
Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study
Simon, D., Preziosi, P., Barrett-Connor, E., Roger, M., Saint-Paul, M., Nahoul, K., & Papoz, L. (1992) · Diabetologia · doi:10.1007/bf00402551 · Cited by 157 · cited 1×
“Cross-sectional studies in healthy men have shown an inverse relationship between total testosterone and free testosterone levels with raised insulin resistance and insulin concentrations.(22,23) Low testosterone levels have also been found to be associated with hypertension.”
BackgroundSimon, D., Charles, M.-A., Lahlou, N., Nahoul, K., Oppert, J.-M., Gouault-Heilmann, M., Lemort, N., Thibult, N., Joubert, E., Balkau, B., et al. (2001) · Diabetes Care · doi:10.2337/diacare.24.12.2149 · Cited by 136 · cited 1×
“8 nmol/L), reported an improvement in insulin sensitivity and a decrease in insulin levels using testosterone or dihydrotestosterone treatment.(31) Testosterone treatment has also been shown to reduce insulin resistance in obese men and decrease total cholesterol in hypogonadal men with coronary artery disease.”
BackgroundSex hormones and hemostatic risk factors for coronary heart disease in men with hypertension
Phillips, G. B., Jing, T.-Y., Resnick, L. M., Barbagallo, M., Laragh, J. H., & Sealey, J. E. (1993) · Journal of Hypertension · doi:10.1097/00004872-199307000-00003 · Cited by 117 · cited 1×
“Low testosterone levels have also been found to be associated with hypertension.(24) Similarly, longitudinal studies have demonstrated that lower testosterone levels independently predict the development of insulin resistance, metabolic syndrome, and type 2 diabetes.”
BackgroundPartial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control
Corrales, J. J., Burgo, R. M., Garcı́a-Berrocal, B., Almeida, M., Alberca, I., González-Buitrago, J. M., Orfao, A., & Miralles, J. M. (2004) · Metabolism · doi:10.1016/j.metabol.2003.12.016 · Cited by 97
Basu, R., Man, C. D., Campioni, M., Basu, A., Nair, K. S., Jensen, M. D., Khosla, S., Klee, G., Toffolo, G., Cobelli, C., et al. (2007) · Diabetes Care · doi:10.2337/dc07-0359 · Cited by 91
Cited by
Suicide and Cardiovascular Death after a Cancer Diagnosis
Fang, F., Fall, K., Mittleman, M. A., Sparén, P., Ye, W., Adami, H.-O., & Valdimarsdóttir, U. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110307 · Cited by 455
Cardiovascular disease after cancer therapy
Aleman, B. M. P., Moser, E. C., Nuver, J., Suter, T. M., Maraldo, M. V., Specht, L., Vrieling, C., & Darby, S. C. (2014) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2014.03.002 · Cited by 168
“Prostate cancer patients may develop an increase in fat mass, a decrease in lean body mass, an adverse lipid profile, and impaired insulin sensitivity early (within 3–6 months) after start of androgen deprivation therapy ADT [49].”
BackgroundInfluentialJoshi, M., Kim, J., D’Alessandro, A., Monk, E., Bruce, K., Elajaili, H., Nozik-Grayck, E., Goodspeed, A., Costello, J. C., & Schlaepfer, I. R. (2020) · Cancers · doi:10.3390/cancers12113431 · Cited by 54
“These later conditions are characteristic of advanced PCa, where androgen deprivation and excess circulating lipids frequently exists [40].”
Background
Metadata
- Authors
- Collier, A., Ghosh, S., McGlynn, B., & Hollins, G.
- Venue
- American Journal of Clinical Oncology
- Published
- 2012-10
- Volume
- 35
- Issue
- 5
- Pages
- 504-509
- ISSN
- 0277-3732 (ISSN-L)
- OpenAlex
- W2332119104
- Cited by
- 74
- References
- 21
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.